TKNO
Alpha Teknova, Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.
Price History
Fundamentals
| Market Cap | $323.02M |
| P/E Ratio (TTM) | - |
| Forward P/E | -24.59 |
| EPS (TTM) | $-0.31 |
| Dividend Yield | - |
| Profit Margin | -41.07% |
| Revenue Growth | 13.10% |
| ROE | -23.92% |
| Debt/Equity | 42.86 |
| Recommendation | None |
| Analyst Target | $9.00 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 76.9 |
| Beta | 0.63 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.68 |
| 52-Week Low | $1.91 |
| 50-Day Avg | $4.28 |
| 200-Day Avg | $3.99 |
| Avg Volume | 165.7K |
| Volume | 1.2K |
Performance Analysis
NEUTRALTKNO presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report